Need professional-grade analysis? Visit stockanalysis.com
$5.52B
N/A
258
N/A
Cogent Biosciences Inc (COGT) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $37.25, up 2.93% from the previous close.
Over the past year, COGT has traded between a low of $4.34 and a high of $42.11. The stock has gained 758.3% over this period. It is currently 11.5% below its 52-week high.
Cogent Biosciences Inc has a market capitalization of $5.52B.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Side-by-side comparison against top Healthcare peers.